Value Added Abiraterone

Value Added Abiraterone
Product Description

Value added Abiraterone 

  •  Abiraterone is a medication used to treat prostate cancer 
  •  The recommended dose is 1,000 mg as a single daily dose that must not be taken with food. 
  •  Administering  with food results up to a 10-fold (AUC) and up to a 17-fold (Cmax) increase in mean systemic exposure of abiraterone, depending on the fat content of the meal. 
  •  The prescriber or patient does not need to worry about consumption of food with Zentiva’s Value added abiraterone. The patient does not need to take Zentiva’s product in fasting condition (one hour before or at least two hours after eating) 
  •  The product is available for Co-development for US and for out licensing in selected EU countries. 
  •  For more details contact Vaibhav Sharma, Head of Value added products ([email protected] )

Read more Show less

Zentiva

  • CZ
  • 2019
    On CPHI since
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Zentiva

  • CZ
  • 2019
    On CPHI since
View company profile

More Products from Zentiva (4)

  • Zent2U - Zentiva B2B Platform

    Product Zent2U - Zentiva B2B Platform

    Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

    - Licensing-out dossiers developed by Zentiva

    - Co-development opportunities by co-financing Zentiva's products in development

    - CMO services by Zentiva in production ...
  • Value Added Dasatinib

    Product Value Added Dasatinib

    Value added Dasatinib (Teaser attached)  •  Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)  •  Current available products on the market are not completely absorbed by those patients ...
  • Innovative combination Finasteride + Tadalafil

    Product Innovative combination Finasteride + Tadalafil

    Innovative combination Finasteride + Tadalafil   • Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe.  • The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of the...
  • CDMO

    Product CDMO

    Services.

Zentiva resources (1)